BCL2 and neoplasm: With 85% of the majority of estrogen receptor positive (ER+) breast cancer patients present with overexpression of the anti-apoptotic protein BCL-2 [3], which is an estrogen-responsive gene promoting tumor cell survival and disease progression by allowing breast cancer cells to evade programmed cell death [10,11,12,13].